Background
As gene therapy development demands stronger human relevance, a new approach is raising the standard. iPSC-based systems are providing a powerful way to model physiologically meaningful human cell types and improve the translational value of potency testing across viral and non-viral delivery platforms.
Watch the webinar replay to hear from Ncardia experts on how iPSC-derived models support reliable vector transduction assessment, quantifiable potency metrics, and functional readouts that align with regulatory expectations.
See how these systems strengthen mechanism-of-action studies, enhance lot release and comparability testing, and deliver greater confidence in gene therapy quality and clinical relevance.